Literature DB >> 11861801

Distinct pathways of apoptosis triggered by FTY720, etoposide, and anti-Fas antibody in human T-lymphoma cell line (Jurkat cells).

Masayuki Fujino1, Xiao-Kang Li, Yusuke Kitazawa, Lei Guo, Mikiko Kawasaki, Naoko Funeshima, Takashi Amano, Seiichi Suzuki.   

Abstract

2-amino-2-[2-(4-octylphenyl)ethyl] propane-1,3-diol hydrochloride (FTY720), a synthetic product derived from a metabolite of Isaria sinclairii, has been demonstrated to have a potent immunosuppressive activity that induces apoptotic cell death in T cells and several other cell lines. In this study, using the human T-lymphoma cell line, Jurkat cells, we investigated the apoptotic signal transduction mediated by FTY720, in particular comparing its role on the cleavage of caspases, with that mediated by etoposide or anti-Fas antibody. All of these agents cleaved caspases, inducing their active form in the affected cells. Pretreatment with a broad caspase inhibitor [benzyloxycarbonyl-Val-Ala-Asp-(Ome) fluoromethyl ketone] markedly decreased the incidence of apoptotic cells induced by FTY720, etoposide, and anti-Fas antibody, through the abrogation of cleavage of Bid, poly(ADP-ribose) polymerase, and caspases 3, 8, and 9. The overexpression of Bcl-2 gene prevented FTY720- and etoposide-mediated apoptosis, but not Fas-mediated apoptosis. In addition, mitochondria were demonstrated to play a critical role in FTY720-triggered cell death, suggesting that this drug has a potent anticancer activity.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11861801     DOI: 10.1124/jpet.300.3.939

Source DB:  PubMed          Journal:  J Pharmacol Exp Ther        ISSN: 0022-3565            Impact factor:   4.030


  12 in total

1.  Rapid induction of medullary thymocyte phenotypic maturation and egress inhibition by nanomolar sphingosine 1-phosphate receptor agonist.

Authors:  Hugh Rosen; Christopher Alfonso; Charles D Surh; Michael G McHeyzer-Williams
Journal:  Proc Natl Acad Sci U S A       Date:  2003-09-03       Impact factor: 11.205

Review 2.  Sphingolipid signaling and hematopoietic malignancies: to the rheostat and beyond.

Authors:  Kenneth C Loh; Dianna Baldwin; Julie D Saba
Journal:  Anticancer Agents Med Chem       Date:  2011-11       Impact factor: 2.505

3.  Development of cell death-based method for the selectivity screening of caspase-1 inhibitors.

Authors:  Puneet Chopra; Shashank Gupta; Sunanda G Dastidar; Abhijit Ray
Journal:  Cytotechnology       Date:  2009-08-05       Impact factor: 2.058

4.  The vaccinia virus K1L gene product inhibits host NF-kappaB activation by preventing IkappaBalpha degradation.

Authors:  Joanna L Shisler; Xiao-Lu Jin
Journal:  J Virol       Date:  2004-04       Impact factor: 5.103

5.  Mouse embryonic stem cells undergo charontosis, a novel programmed cell death pathway dependent upon cathepsins, p53, and EndoG, in response to etoposide treatment.

Authors:  Elisia D Tichy; Zachary A Stephan; Andrew Osterburg; Greg Noel; Peter J Stambrook
Journal:  Stem Cell Res       Date:  2013-02-05       Impact factor: 2.020

6.  FTY720 induces cell cycle arrest and apoptosis of rat glomerular mesangial cells.

Authors:  Jingyu Jiang; Xiaodong Huang; Yi Wang; Aiping Deng; Jianhua Zhou
Journal:  Mol Biol Rep       Date:  2012-05-12       Impact factor: 2.316

7.  Destabilisation of dimeric 14-3-3 proteins as a novel approach to anti-cancer therapeutics.

Authors:  Joanna M Woodcock; Carl Coolen; Katy L Goodwin; Dong Jae Baek; Robert Bittman; Michael S Samuel; Stuart M Pitson; Angel F Lopez
Journal:  Oncotarget       Date:  2015-06-10

8.  Subacute Oral Toxicity Study of a New Type of Cordyceps, Paecilomyces sinclairii, in Sprague-Dawley Rats.

Authors:  Seung Jun Kwack; Byung Mu Lee
Journal:  Toxicol Res       Date:  2009-06-01

Review 9.  Multiple Sclerosis and Cancer: The Ying-Yang Effect of Disease Modifying Therapies.

Authors:  Esther Melamed; Michael William Lee
Journal:  Front Immunol       Date:  2020-01-10       Impact factor: 7.561

Review 10.  The emerging role of FTY720 (Fingolimod) in cancer treatment.

Authors:  Christopher White; Heba Alshaker; Colin Cooper; Matthias Winkler; Dmitri Pchejetski
Journal:  Oncotarget       Date:  2016-04-26
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.